eCite Digital Repository
Zoledronic acid plus methylprednisolone versus zoledronic acid or placebo in symptomatic knee osteoarthritis: a randomized controlled trial
Citation
Cai, G and Laslett, LL and Aitken, D and Cicuttini, F and March, L and Hill, C and Winzenberg, T and Jones, G, Zoledronic acid plus methylprednisolone versus zoledronic acid or placebo in symptomatic knee osteoarthritis: a randomized controlled trial, Therapeutic Advances in Musculoskeletal Disease, 11 pp. 1-12. ISSN 1759-720X (2019) [Refereed Article]
![]() | PDF 1Mb |
Copyright Statement
© The Author(s), 2019. Licensed under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) https://creativecommons.org/licenses/by-nc/4.0/
DOI: doi:10.1177/1759720X19880054
Abstract
Methods: A single-center, double-blind, randomized controlled trial (RCT) was carried out. Adults (aged ⩾50 years) with knee osteoarthritis, significant knee pain [⩾40 mm on a 100 mm visual analog scale (VAS)], and magnetic resonance imaging-detected bone marrow lesion (BML) were randomized to receive a one-off administration of VOLT01, ZA, or placebo. The primary hypothesis was that VOLT01 was superior to ZA in having a lower incidence of acute phase responses (APRs) over 3 days. Secondary hypotheses were that VOLT01 was noninferior to ZA, and both treatments were superior to placebo in decreasing BML size over 6 months and in improving knee pain [Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and VAS] and function (WOMAC) over 3 and 6 months.
Results: A total of 117 patients (62.2 ± 8.1 years, 63 women) were enrolled. The incidence of APRs was similar in the VOLT01 (90%) and ZA (87%) groups (p = 0.74). VOLT01 was superior to ZA in improving knee pain and function after 6 months and noninferior to ZA in reducing BML size. However, BML size change was small in all groups and there were no between-group differences. Compared with placebo, VOLT01 but not ZA improved knee function and showed a trend toward improving knee pain after 6 months.
Conclusions: Administering intravenous methylprednisolone with ZA did not reduce APRs or change knee BML size over 6 months, but in contrast to ZA or placebo, it may have a beneficial effect on symptoms in knee osteoarthritis.
Item Details
Item Type: | Refereed Article |
---|---|
Keywords: | acute phase response, bone marrow lesion, methylprednisolone, noninferiority, zoledronic acid |
Research Division: | Biomedical and Clinical Sciences |
Research Group: | Clinical sciences |
Research Field: | Rheumatology and arthritis |
Objective Division: | Health |
Objective Group: | Clinical health |
Objective Field: | Clinical health not elsewhere classified |
UTAS Author: | Cai, G (Mr Guoqi Cai) |
UTAS Author: | Laslett, LL (Dr Laura Laslett) |
UTAS Author: | Aitken, D (Associate Professor Dawn Aitken) |
UTAS Author: | Winzenberg, T (Professor Tania Winzenberg) |
UTAS Author: | Jones, G (Professor Graeme Jones) |
ID Code: | 136029 |
Year Published: | 2019 |
Web of Science® Times Cited: | 2 |
Deposited By: | Menzies Institute for Medical Research |
Deposited On: | 2019-11-27 |
Last Modified: | 2020-08-04 |
Downloads: | 8 View Download Statistics |
Repository Staff Only: item control page